Zobrazeno 1 - 10
of 322
pro vyhledávání: '"F. Kabbinavar"'
Autor:
David H. Johnson, Roy S. Herbst, Corey J. Langer, Louis Fehrenbacher, William Novotny, Eric Holmgren, Jacques Gaudreault, John Nemunaitis, David M. Jablons, Fairooz F. Kabbinavar, Russell F. DeVore, Lisa A. Damico
Publikováno v:
Journal of Clinical Oncology. 41:2305-2312
Purpose To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. Patients and Methods In a phase II trial, 99 patients were randomly assigned to bevacizum
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Sara A. Hurvitz, Maureen E. Trudeau, William J. Gradishar, Larisa Ryvo, Ming-Shen Dai, Sujith Kalmadi, Cristiano Souza, Eduardo Cronemberger, Suzette Delaloge, Adam Brufsky, Mafalda Oliveira, Vladimir Milovanov, Beverly Moy, Sung Bae Kim, Kiana Keyvanjah, J. Alarcón, Fairooz F. Kabbinavar, Ron Bose, Richard A. Bryce, Cristina Saura, Judith Bebchuk, Barbara Haley, Luciana Landeiro
Publikováno v:
The Oncologist
The oncologist, vol 26, iss 8
Scientia
The oncologist, vol 26, iss 8
Scientia
Background Neratinib has efficacy in central nervous system (CNS) metastases from HER2‐positive metastatic breast cancer (MBC). We report outcomes among patients with CNS metastases at baseline from the phase III NALA trial of neratinib plus capeci
Autor:
Einat S Shmueli, Morteza Raeisi, Benoist Chibaudel, Herbert Hurwitz, Leonard B. Saltz, Fairooz F. Kabbinavar, Niall C. Tebbutt, Axel Grothey, Richard Adams, John Raymond Zalcberg, Takayuki Yoshino, Jean-Baptiste Bachet, Romain Cohen, Lama Sharara, Thierry Andre, Qian Shi, Aimery De Gramont
Publikováno v:
Journal of Clinical Oncology. 41:118-118
118 Background: Anti-VEGF is widely used in the treatment (trt) of metastatic colorectal cancer (mCRC). Only studies with bevacizumab (BEV) have shown survival benefit (bnf) in first line trt. The magnitude of bnf might differ based on the metastatic
Autor:
N.I. Khushalani, H. Shue, C. Gedye, A. Mazumder, S. Sharma, M. Eastgate, M. Majem Tarruella, M. Antonanzas Basa, H. Montaudie, R. Marais-Nieman, L. de la Cruz Merino, A. Clements, L. Mortier, M. Jameson, F. Shojaei, J. Ning, L. Aiyer, M. Gillings, F. Kabbinavar, P. Ascierto
Publikováno v:
Annals of Oncology. 33:S1444
Autor:
Richard M. Goldberg, Leonard B. Saltz, Jean-Yves Doulliard, Aimery de Gramont, Eric Van Cutsem, Christophe Tournigard, Fairooz F. Kabbinavar, John Souglakos, Romain Cohen, Richard Adams, J. Randolph Hecht, John Zalcberg, Eduard Diaz Rubio, Hans-Joachim Schmoll, Matthew T. Seymour, Charles S. Fuchs, Shaheenah Dawood, Volker Heinemann, Paulo M. Hoff, Alan P. Venook, Takayuki Yoshino, Chiara Cremolini, Carsten Bokemeyer, Miriam Koopman, Tim Maughan, Jun Yin, Axel Grothey, Jeffrey P. Meyers, Herbert Hurwitz, Niall C. Tebbutt, Cornelis J. A. Punt, Benoist Chibaudel, Qian Shi
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Therapeutic Advances in Medical Oncology
Therapeutic advances in medical oncology, 13. SAGE Publications Inc.
Therapeutic Advances in Medical Oncology
Therapeutic advances in medical oncology, 13. SAGE Publications Inc.
Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis\ud Show less\ud Jun Yin*, Shaheenah Dawood*, Romain Cohen, Jeff Meyers, John Zalcberg, Takayuki Yo
Autor:
Florian Huemer, Melissa Lynne Johnson, David S. Shames, György Losonczy, Aleksandra Szczesna, Aaron S. Mansfield, Alan Sandler, Maximilian Hochmair, Makoto Nishio, Juan Liu, Libor Havel, W. Lin, S. Lam, F. Kabbinavar, Leora Horn, Martin Reck, Stephen V. Liu, Ariel Lopez-Chavez, Beiying Ding, Maciej Krzakowski, Tony Mok
Publikováno v:
New England Journal of Medicine. 379:2220-2229
Background Enhancing tumor-specific T-cell immunity by inhibiting programmed death ligand 1 (PD-L1)–programmed death 1 (PD-1) signaling has shown promise in the treatment of extensive-stag...
Autor:
Michael A. Vogelbaum, Yaron A. Moshel, Jay-Jiguang Zhu, Tobias Walbert, Michael Salacz, William P. Accomando, Dimitris G. Placantonakis, Kevin Petrecca, Aliz R. Rao, Fairooz F. Kabbinavar, Derek Ostertag, Lyndon Kim, Fabio M. Iwamoto, Steven Brem, Chetan Bettegowda, James Perry, Clark C. Chen, Nicholas Butowski, Joseph Landolfi, David Piccioni, Daniela A. Bota, Daniel J. Hogan, David Cachia, Tiffany T. Montellano, Thian Kheoh, Timothy F. Cloughesy, George J. Kaptain, Harry E. Gruber, Brad Elder, Denise Damek
Publikováno v:
JAMA oncology, vol 6, iss 12
JAMA Oncol
JAMA Oncol
Importance New treatments are needed to improve the prognosis of patients with recurrent high-grade glioma. Objective To compare overall survival for patients receiving tumor resection followed by vocimagene amiretrorepvec (Toca 511) with flucytosine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ce24ce6c4cbe1005077e7cb8405c5b7
https://escholarship.org/uc/item/85t6k5t9
https://escholarship.org/uc/item/85t6k5t9
Autor:
Leora Horn, R De Boer, Stephen V. Liu, Raffaele Califano, A. Sánchez, A. Każarnowicz, Wei Yu, Nina Karaseva, S. Morris, F. Kabbinavar, Marina Chiara Garassino, Martin Reck, Z Andric, S. Lam, S Atagi, X. Wen, C. Quach, Aaron S. Mansfield, J-S. Lee
Background The addition of atezolizumab to carboplatin and etoposide (CP/ET) significantly improved progression-free and overall survival for patients with extensive-stage small-cell lung cancer (ES-SCLC) in the IMpower133 study (NCT02763579). We hav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac995d028bf2d8e31f704fef09e06759
http://www.annalsofoncology.org/article/S0923753419360788/pdf
http://www.annalsofoncology.org/article/S0923753419360788/pdf
Autor:
Santiago Viteri Ramirez, Valentina Boni, Naisargee Shah, Amit Mahipal, Lisa D. Eli, Feng Xu, Jennifer Marie Suga, Alshad S. Lalani, Fairooz F. Kabbinavar, Jonathan W. Goldman, Richard A. Bryce, Barbara Haley
Publikováno v:
Journal of Clinical Oncology. 39:9068-9068
9068 Background: The phase 2 SUMMIT basket trial (NCT01953926) demonstrated efficacy of neratinib in patients with EGFR exon 18-mutant NSCLC [Boni et al. WCLC 2020]. Neratinib also has documented activity in HER2+ metastatic breast cancer with CNS me